MAPT and synucleinopathy: In addition, it seems plausible that CSF1R inhibitors may also block microglia-mediated activation of A1 astrocytes46, which in turn secrete factors that also drive tau pathogenesis; blocking this cellular feed-forward pathway using a different drug targeting microglia led to neuroprotection in a synucleinopathy model of Parkinson’s disease58.